Institute of Tropical Medicine, Nagasaki University
Department of Pediatric Infectious Diseases
Lay-Myint Yoshida is the Professor and Head of the Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Japan. He leads the clinical research group of Nagasaki University-Vietnam research project in Vietnam. He received his medical doctor degree, MBBS (MD) from University of Medical 1, Yangon, Myanmar in 1990 and was trained as a general physician at Yangon General Hospital. He obtained his PhD at Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Japan in 2004. His research area covers abroad range including viral and bacterial pathogens on pneumonia (ARI), vaccine preventable diseases, congenital infection, dengue, HIV drug resistance, etc. He has been working on a population based pediatric acute respiratory infection surveillance in Nha Trang, central Vietnam since 2007. He is the principal investigator of a phase IV PCV reduced dosing schedule study “EVALUATION OF REDUCED DOSE PCV SCHEDULES IN A NAIVE POPULATION IN VIETNAM” funded by the Bill & Melinda Gates Foundation.

Moderator of 1 Session

Session Type
Plenary Session
Date
Wed, 22.06.2022
Session Time
10:30 - 12:00
Room
Grand Ballroom East
Session Description
Please note: Each presentation is followed by 5 to 10 minutes of Q&A. The audience is encouraged to send questions to the speakers from the beginning of their presentations. Q&A time is included in each speaker’s presentation duration, accounting for at least 25% active learning for the maximum registrants anticipated.

Presenter of 1 Presentation

O063 - EVALUATION OF REDUCED DOSE PCV SCHEDULES IN A NAIVE POPULATION IN VIETNAM (ID 838)

Session Type
Parallel Session
Date
Wed, 22.06.2022
Session Time
15:05 - 16:50
Room
Grand Ballroom Centre
Lecture Time
16:47 - 16:55

Abstract

Background

We investigated whether a mature Pneumococcal Conjugate Vaccine (PCV) schedule with a single priming and a booster dose (1p+1) offers non-inferior protection compared to 3 dose schedules (2p+1 and 3p+0).

Methods

Between October 2016 and October 2020 we conducted a cRCT with four arms using PCV10 in a 1p+1, 0p+1, 2p+1 or 3p+0 schedule, in 24 communes in Nha Trang, Vietnam, a PCV-naïve population. A catch-up campaign was offered to all <3y olds at the start of vaccination in February 2017. Annual carriage surveys in 1440 infants, 1440 toddlers and their mothers were conducted. Vaccine type (VT) carriage was determined by lytA RT-PCR positivity, culture and microarray serotyping. The primary endpoint was non-inferiority of VT carriage in infants in 1p+1 vs 2p+1 and 3p+0 arms; non-inferiority was defined as an absolute difference of less than 5%.

Results

VT carriage in infants before PCV was 11.6% (161/1383). In 2020, VT carriage in infants had reduced to 2.0% (7/353) vs 1.5% (5/343) and 1.2% (4/331) in 1p+1, 2p+1, and 3p+0 arms respectively: a non-inferior difference of 0.5% (-1.4, 2.5%) and 0.8% (-1.1, 2.7%). Vaccine cross reactive ST6A prevalence in infants was 6.4% (89/1383) before PCV use and reduced to 3.3% (12/353) vs 2.9% (10/343) and 0.9% (3/331) in 1p+1, 2p+1, and 3p+0 arms in 2020. Reductions were similar for toddlers and marginally lower for the 0p+1 arm.

Conclusions

The 1p+1 was non-inferior to 3 dose PCV10 schedules in sustaining combined direct and indirect protection against carriage in infants.

Hide